MindRank Founder Dr. Zhangming Niu Named to Fortune China's '40 Under 40' List for 2024

The "Fortune China 40 Under 40" list has been published since 2011 and isOne of the authoritative selections for the most influential young leaders.The selection criteria for this list include dimensions such as innovation, social responsibility, business models, and technological innovation, aiming to identify outstanding innovators, value creators, and transformers of the younger generation in China.

As the founder and CEO of MindRank, Zhangming Niu has many years of R&D management experience in the AI pharmaceuticals industry and has served as a director/CTO of a German mainboard-listed AI healthcare company. With a long-term focus on AI-driven drug discovery research, Zhangming Niu has published dozens of peer-reviewed papers, including in Nature, Cell series journals, and top artificial intelligence conferences, and has led the development of MindRank's leading AI pharmaceutical platform, featuring Molecule Pro at its core, along with a series of related technologies and practical applications.

Guided by the vision of "Technology for Good," to develop high-quality innovative drugs as soon as possible and make people's lives better is the original aspiration and mission that Niu Zhangming and the MindRank team have always adhered to.

In August 2023, as the only selected participant from mainland China, "MindRank" was chosen for an AI + anti-aging innovative therapy R&D project in collaboration with top international universities, initiated jointly by Wellcome Leap and the Temasek Trust Foundation.Dynamic Resilience Program,Secured millions of dollars in funding. During the same period, the company was also successfully listed in Forbes.“Forbes Asia 100 to Watch”List, only 11 companies from mainland China made the cut.

Currently, MindRank's industrial-grade one-stop AI-driven new drug R&D platform has efficiently produced multiple PCC molecules for difficult drug targets with the potential to be first-in-class or best-in-class.MindRank's self-developed GLP-1RA small molecule oral drug MDR-001 is proceeding smoothly in Phase II clinical trials.Four other innovative drugs targeting tumors and metabolism have entered the IND-Enabling stage.

Original link:

Fortune, founded by American publishing magnate Henry R. Luce in 1929, has been a focal point in the economic community with its significant influence since launching the Fortune 500 rankings in 1955. FORTUNE China, first published in 1996, advances and develops business topics. It looks globally while staying close to China — using an objective and balanced perspective to draw historical wisdom and foresee future trends; the business stories it reports and discloses have a crucial impact on today’s world and the future.

MindRank is a clinical-stage AI-driven innovative drug discovery company. The company's vision is to continuously deliver differentiated and high clinical value drug candidates by promoting the integration of various cutting-edge technologies in artificial intelligence and new drug development, thereby helping more lives regain health.

MindRank's AI pharmaceutical solutions were rated by the authoritative European and American institution Deep Pharma Intelligence as one of the "11 most important AI drug R&D breakthrough achievements globally from 2018 to 2020." In 2023, it was selected for Forbes' "Forbes Asia 100 to Watch" list, with only 11 startups from mainland China making the list.

For more information, please visit the website: www.mindrank.ai

Cooperation: bd@mindrank.ai

Other: info@mindrank.ai